Bellevue Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bellevue Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-169	Closed	-$31K	–	609
2021 Q2	$31K	Hold	169	–	–	0.02%	235
2021 Q1	$26K	Hold	169	–	–	0.02%	261
2020 Q4	$27K	Hold	169	–	–	0.02%	245
2020 Q3	$19K	Buy	169 +30	+22%	+$3.24K	0.01%	265
2020 Q2	$16K	Hold	139	–	–	0.02%	289
2020 Q1	$15K	Buy	+139	New	+$13.6K	0.02%	299

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bellevue Asset Management's ALXN Position: Q3 2021 in Review

Bellevue Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 169 shares — an estimated $31K sold.

Bellevue Asset Management first reported a position in ALXN in Q1 2020 and held it in 6 quarters. The position peaked at $31K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Bellevue Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Bellevue Asset Management sold 169 Alexion Pharmaceuticals shares in Q3 2021, an estimated $31K.
Bellevue Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 6 quarters.
Bellevue Asset Management's Alexion Pharmaceuticals position peaked at $31K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bellevue Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.